MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

Abstract Cervical cancer (CC) is one of the most common malignancies in women. Paclitaxel is the front-line chemotherapeutic agent for treating CC. However, its therapeutic efficacy is limited because of chemoresistance, the mechanism of which remains poorly understood. Here, we used microRNA (miRNA) arrays to compare miRNA expression levels in the CC cell lines, HeLa and CaSki, with their paclitaxel resistance counterparts, HeLa/PR and CaSki/PR. We demonstrate that miR-125a was one of most significantly downregulated miRNAs in paclitaxel-resistant cells, which also acquired cisplatin resistance. And that the upregulation of miR-125a sensitized HeLa/PR and CaSki/PR cells to paclitaxel both in vitro and in vivo and to cisplatin in vitro. Moreover, we determined that miR-125a increased paclitaxel and cisplatin sensitivity by downregulating STAT3. MiR-125a enhanced paclitaxel and cisplatin sensitivity by promoting chemotherapy-induced apoptosis. Clinically, miR-125a expression was associated with an increased responsiveness to paclitaxel combined with cisplatin and a more favorable outcome. These data indicate that miR-125a may be a useful method to enable treatment of chemoresistant CC and may also provide a biomarker for predicting paclitaxel and cisplatin responsiveness in CC.

Download Full-text

Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer

Cell Death and Disease ◽

10.1038/s41419-020-2735-2 ◽

2020 ◽

Vol 11 (7) ◽

Cited By ~ 2

Author(s):

Xingyu Fang ◽

Guanglei Zhong ◽

Yuhan Wang ◽

Zhongqiu Lin ◽

Rongchun Lin ◽

...

Keyword(s):

Cervical Cancer ◽

Animal Studies ◽

Cisplatin Resistance ◽

Suppressor Gene ◽

Tumour Suppressor Gene ◽

Luciferase Reporter ◽

Poor Overall Survival ◽

Cisplatin Sensitivity

Abstract Cisplatin resistance is a major challenge in cervical cancer (CC) chemotherapy. Growth arrest‐specific 5 (GAS5) has been reported to be a tumour suppressor gene in CC. However, the mechanism of GAS5 in chemoresistance remains undetermined. Our research evaluated GAS5 expression in normal and CC tissues by qPCR and in situ hybridization (ISH). Statistical analysis was conducted to analyse the association of GAS5 expression with survival. Biochemical methods were used to screen upstream and downstream regulators of GAS5. Then, interactions were confirmed by ChIP, RNA pull-down, RNA immunoprecipitation (RIP), dual-luciferase reporter and real-time PCR assays. The cisplatin sensitivity of GAS5-overexpressing CC cells was demonstrated in vitro and in vivo. The results showed that low GAS5 expression was correlated with poor overall survival. Mechanistically, GAS5 was transcriptionally modulated by P-STAT3 and served as a competing endogenous RNA (ceRNA) of miR-21 to indirectly affect cisplatin sensitivity through PDCD4 regulation in CC cells. Animal studies confirmed that GAS5 enhanced cisplatin sensitivity and promoted PDCD4 expression in vivo. GAS5 was regulated by P-STAT3 and affected the sensitivity of CC to cisplatin-based chemotherapy through the miR-21/PDCD4 axis. This result may provide new insight into cisplatin-based therapy.

Download Full-text

CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis

Molecular Cancer ◽

10.1186/s12943-021-01453-0 ◽

2021 ◽

Vol 20 (1) ◽

Author(s):

Shenglong Li ◽

Fei Liu ◽

Ke Zheng ◽

Wei Wang ◽

Enduo Qiu ◽

...

Keyword(s):

Cell Lines ◽

Cisplatin Resistance ◽

Osteogenic Sarcoma ◽

Mg63 Cell ◽

Circular Rnas ◽

Rna Immunoprecipitation ◽

Cisplatin Sensitivity ◽

Regulatory Effects

Abstract Background Circular RNAs (circRNAs), a class of noncoding RNAs (ncRNAs), may modulate gene expression by binding to miRNAs. Additionally, recent studies show that circRNAs participate in some pathological processes. However, there is a large gap in the knowledge about circDOCK1 expression and its biological functions in osteogenic sarcoma (OS). Methods Differentially expressed circRNAs in OS cell lines and tissues were identified by circRNA microarray analysis and quantitative real-time PCR (qRT–PCR). To explore the actions of circDOCK1 in vivo and in vitro, circDOCK1 was knocked down or overexpressed. To assess the binding and regulatory associations among miR-339-3p, circDOCK1 and IGF1R, we performed rescue experiments, RNA immunoprecipitation (RIP), RNA pulldown assays and dual-luciferase assays. Moreover, we performed apoptosis assays to reveal the regulatory effects of the circDOCK1/miR-339-3p/IGF1R axis on cisplatin sensitivity. Results CircDOCK1 expression remained stable in the cytoplasm and was higher in OS tissues and cells than in the corresponding controls. Overexpression of circDOCK1 increased oncogenicity in vivo and malignant transformation in vitro. In the U2OS and MG63 cell lines, circDOCK1 modulated tumor progression by regulating IGF1R through sponging of miR-339-3p. Additionally, in the U2OS/DDP and MG63/DDP cell lines, cisplatin sensitivity was regulated by circDOCK1 via the miR-339-3p/IGF1R axis. Conclusions CircDOCK1 can promote progression and regulate cisplatin sensitivity in OS via the miR-339-3p/IGF1R axis. Thus, the circDOCK1/miR-339-3p/IGF1R axis may be a key mechanism and therapeutic target in OS.

Download Full-text

The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity

10.1101/2021.03.04.433676 ◽

2021 ◽

Author(s):

Robert T. Jones ◽

Andrew Goodspeed ◽

Maryam C. Akbarzadeh ◽

Mathijs Scholtes ◽

Hedvig Vekony ◽

...

Keyword(s):

Bladder Cancer ◽

Cisplatin Resistance ◽

Treatment Resistance ◽

Anion Channel ◽

List Type ◽

Cancer Models ◽

Cisplatin Sensitivity ◽

Cancer Types

ABSTRACTDespite routine use of platinum-based chemotherapeutics across diverse cancer types, there remains a need to improve efficacy and patient selection for treatment. A multi-omic assessment of five human bladder cancer cell lines and their chemotherapy resistant derivatives, coupled with whole-genome CRISPR screens were used to identify puromycin- sensitive aminopeptidase, NPEPPS, as a novel functional driver of treatment resistance to cisplatin. Depletion of NPEPPS resulted in enhanced cellular cisplatin import, sensitization of resistant cancer cells to cisplatin in vitro and in vivo. Pharmacologic inhibition of NPEPPS with tosedostat in cells and in chemoresistant, patient-derived tumor organoids improved response to cisplatin. Depletion of LRRC8A and LRRC8D, two subunits of the volume regulated anion channel (VRAC), a known importer of intracellular cisplatin, enhanced resistance to cisplatin. Linking NPEPPS function to VRAC cisplatin import supports NPEPPS as a driver of cisplatin resistance and by virtue of clinically available inhibitors, the potential for rapid clinical translation.HIGHLIGHTS∙CRISPR screens with multi-omics identify NPEPPS as a driver of cisplatin resistance∙NPEPPS depletion in multiple bladder cancer models enhances cisplatin sensitivity∙LRRC8A and LRRC8D loss increase resistance to cisplatin in CRISPR screens∙Unique resource of functional and multi-omic data is provided to the community

Download Full-text

CircRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation

Journal of Experimental & Clinical Cancer Research ◽

10.1186/s13046-021-02149-5 ◽

2021 ◽

Vol 40 (1) ◽

Author(s):

Zhenchuan Liu ◽

Shaorui Gu ◽

Kaiqin Wu ◽

Lei Li ◽

Chenglai Dong ◽

...

Keyword(s):

Cancer Progression ◽

Cisplatin Resistance ◽

Critical Role ◽

Circular Rnas ◽

Major Barrier ◽

Downstream Target ◽

Cisplatin Sensitivity

Abstract Background Cisplatin-based chemotherapy is a mainstay systematic therapy for advanced esophageal squamous cell carcinoma (ESCC), and cisplatin resistance, which is not uncommon, is the major barrier to improving patient outcomes. Circular RNAs (circRNAs) are novel noncoding RNAs that are implicated in cancer progression, but their involvement in modulating cisplatin responsiveness in ESCC remains unknown. Methods Bioinformatics analysis was used to profile and identify the circRNAs involved in cisplatin responsiveness in ESCC. The chemosensitive role of cDOPEY2 was confirmed both in vitro and in vivo. The molecular mechanism of cDOPEY2 was investigated by mass spectrometry, immunoprecipitation, and ubiquitination analyses. Results We report that a novel circRNA (cDOPYE2, hsa_circ_0008078) was markedly downregulated in cisplatin-resistant ESCC cells (ESCC-CR) compared with parental chemosensitive cells. Re-expression of cDOPEY2 substantially enhanced the cell-killing ability of cisplatin by augmenting the apoptotic process in ESCC-CR cells, which was achieved by decreasing the abundance of the antiapoptotic protein Mcl-1. Mechanistically, we showed that cDOPEY2 acted as a protein scaffold to enhance the interaction between the cytoplasmic polyadenylation element binding protein (CPEB4) and the E3 ligase TRIM25, which in turn facilitated the ubiquitination and degradation of CPEB4. The increased Mcl-1 expression in ESCC-CR cells was dependent on the binding of CPEB4 to its untranslated mRNA, and depletion of CPEB4 mediated by cDOPEY2 reversed this effect. Rescue experiments confirmed that the critical role of cDOPEY2 in maintaining cisplatin sensitivity was dependent on the depletion of CEPB4 and its downstream target Mcl-1. Clinical and in vivo data further corroborated the significant relevance of cDOPEY2 to cisplatin responsiveness in ESCC. Conclusions We provide evidence that cDOPEY2 inhibits CPEB4-mediated Mcl-1 translation by promoting the ubiquitination and degradation of CPEB4 to alleviate cisplatin resistance, indicating that cDOPEY2 may serve as a valuable biomarker and potential therapeutic target in ESCC.

Download Full-text

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux

Cancers ◽

10.3390/cancers13143467 ◽

2021 ◽

Vol 13 (14) ◽

pp. 3467

Author(s):

Yujie Zhao ◽

Xiaoting Hong ◽

Xiong Chen ◽

Chun Hu ◽

Weihong Lu ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Cisplatin Resistance ◽

Progression Free Survival ◽

Platinum Resistance ◽

Lysosomal Degradation ◽

Free Survival ◽

Cisplatin Sensitivity

Whilst researches elucidating a diversity of intracellular mechanisms, platinum-resistant epithelial ovarian cancer (EOC) remains a major challenge in the treatment of ovarian cancer. Here we report that Exo70, a key subunit of the exocyst complex, contributes to both innate and acquired cisplatin resistance of EOC. Upregulation of Exo70 is observed in EOC tissues and is related to platinum resistance and progression-free survival of EOC patients. Exo70 suppressed the cisplatin sensitivity of EOC cells through promoting exocytosis-mediated efflux of cisplatin. Moreover, cisplatin-induced autophagy-lysosomal degradation of Exo70 protein by modulating phosphorylation of AMPK and mTOR, thereby reducing the cellular resistance. However, the function was hampered during prolonged cisplatin treatment, which in turn stabilized Exo70 to facilitate the acquired cisplatin resistance of EOC cells. Knockdown of Exo70, or inhibiting exocytosis by Exo70 inhibitor Endosidin2, reversed the cisplatin resistance of EOC cells both in vitro and in vivo. Our results suggest that Exo70 overexpression and excessive stability contribute to innate and acquired cisplatin resistance through the increase in cisplatin efflux, and targeting Exo70 might be an approach to overcome cisplatin resistance in EOC treatment.

Download Full-text

Novel genes mediating cisplatin resistance in head and neck cancer

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22135 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22135-e22135

Author(s):

M. Gasco ◽

N. Syed ◽

H. Coley ◽

I. Colantonio ◽

M. Merlano ◽

...

Keyword(s):

Head And Neck ◽

Clinical Utility ◽

Cisplatin Resistance ◽

Novel Genes ◽

Acquired Drug Resistance ◽

Specific Pcr ◽

Micro Array ◽

Cisplatin Sensitivity

e22135 Background: Chemo-radiotherapy with cisplatin-based regimens offers the possibility of cure to a subset of patients with surgically non-resectable squamous carcinomas of the head and neck (HNSCC), but outcome is frequently limited by acquired drug resistance. We have sought novel genes mediating cisplatin resistance in HNSCC. Methods: We derived in vitro cisplatin resistant variants of the HN5 HNSCC cell line and performed micro-array anaylsis to identify differentially expressed genes. Differences in gene expression were confirmed by qPCR and /or western blotting. Methylation-dependent transcriptional silencing of down-regulated genes was studied by bisulphate sequencing and methylation specific PCR. Selected genes were further analysed in a cohort of stage III and IV HNSCC patients treated with cisplatin-based chemo-radiotherapy. Results: We have identified a panel of genes in which changes in expression occur with acquisition of cisplatin resistance both in vitro and, some cases, in vivo. Up-regulated genes include TAOK1, BZW1 and RECQL, whereas down-regulated genes include FAM83D, PAFAH1B2, DLL1, ABPA1 and FH. Conclusions: We report the identification of a novel panel of genes which function as determinants of cisplatin sensitivity. Analysis of expression and/or epigenetic regulation of these genes may have clinical utility in prediction of patients likely to respond to highly toxic combined modality chemo-radiotherapy. No significant financial relationships to disclose.

Download Full-text

Targeted delivery of “copper carbonate” nanoparticles to cancer cells in vivo

Toxicology Research ◽

10.1039/c5tx00212e ◽

2015 ◽

Vol 4 (6) ◽

pp. 1604-1612 ◽

Cited By ~ 8

Author(s):

Arindam Pramanik ◽

Dipranjan Laha ◽

Sourav Chattopadhyay ◽

Sandeep Kumar Dash ◽

Somenath Roy ◽

...

Keyword(s):

Cervical Cancer ◽

Targeted Delivery ◽

Cancer Cell Line ◽

Cervical Cancer Cell Line ◽

Copper Carbonate ◽

Human Cervical Cancer Cell ◽

Induced Apoptosis ◽

Human Cervical Cancer

Novel CuCO3 nanoparticles induced apoptosis in a human cervical cancer cell line. The folic acid mediated targeting of the CuCO3 receptor was studied in vitro & in vivo.

Download Full-text

Circular RNA circARNT2 Suppressed The Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting The miR-155-5p/PDK1 Axis

10.21203/rs.3.rs-39627/v1 ◽

2020 ◽

Author(s):

Hanqin Weng ◽

Linhui Cao ◽

Xiaochun Chen ◽

Liqing Ye ◽

Weijian Feng ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cell Proliferation ◽

Cell Lines ◽

Noncoding Rna ◽

Cisplatin Resistance ◽

Circular Rna ◽

Pcr Analysis ◽

Cisplatin Sensitivity

Abstract Background: Circular RNA (circRNA) is a novel subclass of noncoding-RNA molecules that participate in development and progression of a variety of human diseases via sponging microRNAs (miRNAs). Until now, the contributions of circRNAs in chemoresistance of hepatocellular carcinoma (HCC) remain largely unknown.Methods: In the present study, we aimed to investigate the role of circRNA in cisplatin resistance of HCC. We investigated the expression of circRNAs in 5 paired cisplatin-sensitive and cisplatin-resistant HCC tissues by microarray analysis. The qRT-PCR analysis was to investigate the expression pattern of circARNT2 in HCC patient tissues and cell lines. Then, the effects of circARNT2 on cisplatin resistance, cell proliferation, and apoptosis were assessed in HCC in vitro and in vivo.Results: CircARNT2 was significantly upregulated in HCC tissues and cell lines. Overexpression of circARNT2 in HCC was significantly correlated with aggressive characteristics and served as an independent risk factor for overall survival in patients with HCC. In vitro experiments showed that knockdown of circARNT2 inhibited cell proliferation and enhances the cisplatin sensitivity of HCC cells. Furthermore, circARNT2 facilitates HCC progression in vivo. We demonstrated that circARNT2 acts as a sponge for miR-155-5p and verified that PDK1 is a novel target of miR-155-5p.Conclusion: In summary, our study demonstrated that circARNT2 modulates cisplatin resistance through miR-155-5p/PDK1 pathway. Our findings indicated that circARNT2 may serve as a promising therapeutic target for overcoming cisplatin resistance for HCC.

Download Full-text

Microrna-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma By Repressing Wnt-16 and AKT1 and Is a Promising Predictive Biomarker for Patients Survival

Blood ◽

10.1182/blood.v124.21.1638.1638 ◽

2014 ◽

Vol 124 (21) ◽

pp. 1638-1638

Author(s):

Qingqing Cai ◽

Dong Qian ◽

Kailin Chen ◽

Dan Xie ◽

Huilan Rao ◽

...

Keyword(s):

T Cell ◽

Poor Prognosis ◽

Chemotherapeutic Agent ◽

Ectopic Expression ◽

Lymphoblastic Lymphoma ◽

Serum Starvation ◽

Down Regulation ◽

Induced Apoptosis

Abstract Background: De-regulation of microRNA (miRNA) has been extensively investigated in both Hodgkin (HL) and non-Hodgkin lymphomas (NHL), however, little is known about the roles of miRNAs in T-cell lymphoblastic lymphoma (T-LBL). To understand the involvement of miRNAs in the development and treatment of (T-LBL), miRNA profiles were compared between tumor and corresponding non-tumor tissues. Methods: miRCURY LNA array was used to generate miRNA expressing profile. Real-time quantitative PCR and immunohistochemistry (IHC) were applied to detect the expression of miR-374b, AKT1 and Wnt16 in T-LBL samples. Dual-luciferase reporter assay was conducted to confirm target associations of miR-374b. The tumor suppressive effect of miR-374b was determined by both in-vitro and in-vivo studies. Results: The expression of 380 miRNAs was evaluated in five human T-LBL tissues and correspondence normal peripheral blood T-cells by microRNA microarrays. The down-regulation of miR-374b was frequently detected in primary T-LBL tissues, which was significantly associated with patients worse overall survival (P<0.001) and increasing risk of recurrence (P=0.012). Functional assays demonstrated that miR-374b could suppress T-NHL cells proliferation in vitro and in vivo. Furthermore, miR-374b could also sensitize cells to both serum starvation- and chemotherapeutic agent-induced apoptosis. Significantly, subsequent investigation characterized two AKT pathway associated molecules, AKT1 and Wnt16, as direct targets of miR-374b and account for the effect of miR-374b in T-NHL cells. Consistently, in tissues of our T-LBL patients, AKT1 and Wnt16 expression was inversely correlated with miR-374b levels, and could also be independent predictors of recurrence and survival of these patients. Conclusions: Our data highlight the molecular etiology and clinical significance of miR-374b in T-LBL. Targeting miR-374b may represent a new therapeutic strategy to improve the therapy effect and survival for T-LBL patients. Figure 1: Down-regulation of miR-374b is associated with poor prognosis of T-LBL Figure 1:. Down-regulation of miR-374b is associated with poor prognosis of T-LBL Figure 2: ectopic expression of miR-374b suppress T-NHL cells proliferation and sensitize cells to both serum starvation- and chemotherapeutic agent-induced apoptosis Figure 2:. ectopic expression of miR-374b suppress T-NHL cells proliferation and sensitize cells to both serum starvation- and chemotherapeutic agent-induced apoptosis Figure 3: Wnt16 and AKT1 are direct targets of miR-374b Figure 3:. Wnt16 and AKT1 are direct targets of miR-374b Disclosures No relevant conflicts of interest to declare.

Download Full-text

Cationic Channel TRPV2 Overexpression Promotes Resistance to Cisplatin-Induced Apoptosis in Gastric Cancer Cells

Frontiers in Pharmacology ◽

10.3389/fphar.2021.746628 ◽

2021 ◽

Vol 12 ◽

Author(s):

Simona Laurino ◽

Pellegrino Mazzone ◽

Vitalba Ruggieri ◽

Pietro Zoppoli ◽

Giovanni Calice ◽

...

Keyword(s):

Gastric Cancer ◽

Flow Cytometry ◽

Cell Lines ◽

Cisplatin Resistance ◽

Inverse Correlation ◽

Gastric Cancer Cells ◽

Aberrant Expression ◽

Cisplatin Sensitivity ◽

Induced Apoptosis

Gastric cancer (GC) is characterized by poor efficacy and modest clinical impact of current therapies, in which apoptosis evasion is relevant. Intracellular calcium homeostasis dysregulation is associated with apoptosis escaping, and aberrant expression of calcium regulator genes could promote GC drug resistance. Since we previously found a prognostic value for TRPV2 calcium channel expression in GC, we aimed to characterize the role of TRPV2 in cisplatin resistance. Using the TCGA-STAD dataset, we performed a differential gene expression analysis between GC samples in upper and lower tertiles of TRPV2 expression, and then through a gene set analysis, we highlighted the enriched ontology and canonical pathways. We used qRT-PCR to assess TRPV2 expression in three GC cell lines and flow cytometry to evaluate cisplatin-induced cell death rates. Calcium green-1-AM assay was used to estimate differences in intracellular Ca2+ concentrations after inhibition of TRPV2. We engineered AGS cell line to overexpress TRPV2 and used confocal microscopy to quantify its overexpression and localization and flow cytometry to evaluate their sensitivity to cisplatin. Consistent with our hypothesis, among enriched gene sets, we found a significant number of those involved in the regulation of apoptosis. Subsequently, we found an inverse correlation between TRPV2 expression and sensitivity to cisplatin in GC cell lines. Moreover, we demonstrated that inhibition of TRPV2 activity by tranilast blocks the efflux of Ca2+ ions and, in combination with cisplatin, induced a significant increase of apoptotic cells (p = 0.004). We also demonstrated that TRPV2 exogenous expression confers a drug-resistant phenotype, and that tranilast is able to revert this phenotype, restoring cisplatin sensitivity. Our findings consistently suggested that TRPV2 could be a potential target for overcoming cisplatin resistance by promoting apoptosis. Notably, our data are a prerequisite for the potential reposition of tranilast to the treatment of GC patients and anticipate the in vivo evaluation.

Download Full-text